Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
ODI Pharma AB ("ODI" or the "Company") hereby publishes its half-year report for the period July 2025 - December 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.
Second quarter (2025-10-01 - 2025-12-31)
- The Group's net sales amounted to SEK 10,932,119 (0).
- The Group's profit after financial items amounted to SEK 1,298,597 (-2,562,520).
- Result per share amounted to SEK 0.07 (-0.16).*
Six months (2025-07-01 - 2025-12-31)
- The Group's net sales amounted to SEK 16,900,262 (-4,965).
- The Group's profit after financial items amounted to SEK 1,255,378 (-3,953,290).
- Result per share amounted to SEK 0.07 (-0.25).*
- The solidity as of 2025-12-31 was 19% (7%).**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of December 2025, amounted to 18,348,419 (15,915,034) shares. The result per share based on the average number of shares of 18,348,419 (15,915,034) amounts to SEK 0.07 (-0.25) for the first six months 2025-07-01 to 2025-12-31.
** Solidity: Equity divided by total capital.
Highlights during the second quarter
- ODI Pharma AB announced a reverse profit warning following significantly stronger revenue development in Q2 2025/2026 (October-December 2025), with preliminary unaudited revenues of approximately SEK 11 million, corresponding to an increase of approximately 84.3 percent compared to Q1 2025/2026 and a substantial improvement compared to the corresponding quarter of the previous fiscal year, when revenues amounted to SEK 0.
Highlights after the end of the period
- ODI Pharma repaid EUR 100,000 in outstanding debt, corresponding to approximately SEK 1.1 million, strengthening the Company's financial position and reducing leverage.
"The return to profitability marks an important step for ODI Pharma. Following a period of operational adjustments, we are now operating in a more stable environment with improved predictability in deliveries and sales. We have progressed substantially in establishing ODI Pharma as a key player in the Polish market and our focus remains on building out our business further."
- Volker Wiederrich, Chairman of the Board
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.